BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25501130)

  • 1. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study.
    Klauschen F; Wienert S; Schmitt WD; Loibl S; Gerber B; Blohmer JU; Huober J; Rüdiger T; Erbstößer E; Mehta K; Lederer B; Dietel M; Denkert C; von Minckwitz G
    Clin Cancer Res; 2015 Aug; 21(16):3651-7. PubMed ID: 25501130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
    Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
    Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
    Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
    Breast Cancer Res Treat; 2018 May; 169(1):33-42. PubMed ID: 29349710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
    Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
    Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
    BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
    Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
    von Minckwitz G; Müller BM; Loibl S; Budczies J; Hanusch C; Darb-Esfahani S; Hilfrich J; Weiss E; Huober J; Blohmer JU; du Bois A; Zahm DM; Khandan F; Hoffmann G; Gerber B; Eidtmann H; Fend F; Dietel M; Mehta K; Denkert C
    J Clin Oncol; 2011 Jun; 29(16):2150-7. PubMed ID: 21519019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
    Robertson S; Acs B; Lippert M; Hartman J
    Breast Cancer Res Treat; 2020 Aug; 183(1):161-175. PubMed ID: 32572716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer.
    von Minckwitz G; Schmitt WD; Loibl S; Müller BM; Blohmer JU; Sinn BV; Eidtmann H; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Rüdiger T; Erbstoesser E; Fasching PA; Karn T; Müller V; Jackisch C; Denkert C
    Clin Cancer Res; 2013 Aug; 19(16):4521-31. PubMed ID: 23812670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
    Loibl S; Müller BM; von Minckwitz G; Schwabe M; Roller M; Darb-Esfahani S; Ataseven B; du Bois A; Fissler-Eckhoff A; Gerber B; Kulmer U; Alles JU; Mehta K; Denkert C
    Breast Cancer Res Treat; 2011 Nov; 130(2):477-87. PubMed ID: 21837479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
    Pliarchopoulou K; Kalogeras KT; Kronenwett R; Wirtz RM; Eleftheraki AG; Batistatou A; Bobos M; Soupos N; Polychronidou G; Gogas H; Samantas E; Christodoulou C; Makatsoris T; Pavlidis N; Pectasides D; Fountzilas G
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):245-55. PubMed ID: 23096218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.
    Lee J; Im YH; Lee SH; Cho EY; Choi YL; Ko YH; Kim JH; Nam SJ; Kim HJ; Ahn JS; Park YS; Lim HY; Han BK; Yang JH
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):569-77. PubMed ID: 17508214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
    Abubakar M; Orr N; Daley F; Coulson P; Ali HR; Blows F; Benitez J; Milne R; Brenner H; Stegmaier C; Mannermaa A; Chang-Claude J; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RA; Seynaeve C; Figueroa J; Sherman ME; Lissowska J; Hewitt S; Eccles D; Hooning MJ; Hollestelle A; Martens JW; van Deurzen CH; ; Bolla MK; Wang Q; Jones M; Schoemaker M; Wesseling J; van Leeuwen FE; Van 't Veer L; Easton D; Swerdlow AJ; Dowsett M; Pharoah PD; Schmidt MK; Garcia-Closas M
    Breast Cancer Res; 2016 Oct; 18(1):104. PubMed ID: 27756439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
    Sonnenblick A; Francis PA; Azim HA; de Azambuja E; Nordenskjöld B; Gutiérez J; Quinaux E; Mastropasqua MG; Ameye L; Anderson M; Lluch A; Gnant M; Goldhirsch A; Di Leo A; Barnadas A; Cortes-Funes H; Piccart M; Crown J
    Eur J Cancer; 2015 Aug; 51(12):1481-9. PubMed ID: 26074397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
    Noske A; Loibl S; Darb-Esfahani S; Roller M; Kronenwett R; Müller BM; Steffen J; von Toerne C; Wirtz R; Baumann I; Hoffmann G; Heinrich G; Grasshoff ST; Ulmer HU; Denkert C; von Minckwitz G
    Breast Cancer Res Treat; 2011 Feb; 126(1):109-17. PubMed ID: 21190079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl2 and Ki67 refine prognostication in luminal breast cancers.
    Chen LY; Tsang JY; Ni YB; Chan SK; Chan KF; Zhang S; Tse GM
    Breast Cancer Res Treat; 2015 Feb; 149(3):631-43. PubMed ID: 25648135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
    Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
    Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
    Penault-Llorca F; André F; Sagan C; Lacroix-Triki M; Denoux Y; Verriele V; Jacquemier J; Baranzelli MC; Bibeau F; Antoine M; Lagarde N; Martin AL; Asselain B; Roché H
    J Clin Oncol; 2009 Jun; 27(17):2809-15. PubMed ID: 19380452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.